PD
KYTX icon

Point72 (DIFC)’s Kyverna Therapeutics KYTX Stock Holding History

Point72 (DIFC)’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,700
Closed -$5.22K – 1982
2025
Q2 		$5.22K Sell
1,700
-384
-18% -$950 ﹤0.01% 1376
2025
Q1 		$4.02K Buy
+2,084
New +$6.16K ﹤0.01% 1533
2024
Q4 		– Sell
-968
Closed -$4.74K – 1966
2024
Q3 		$4.74K Buy
+968
New +$7.46K ﹤0.01% 1304
2024
Q2 		– Sell
-60,800
Closed -$1.51M – 1986
2024
Q1 		$1.51M Buy
+60,800
New +$1.7M 0.05% 465

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 (DIFC)'s KYTX Position: Q3 2025 in Review

Point72 (DIFC) sold out of Kyverna Therapeutics (KYTX) in Q3 2025, closing a stake of 1,700 shares — an estimated $5.22K sold.

Point72 (DIFC) first reported a position in KYTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.51M in Q1 2024. 75 funds tracked by Wall St. Rank hold KYTX as of Q3 2025.

  • Point72 (DIFC) reported no remaining Kyverna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 1,700 Kyverna Therapeutics shares in Q3 2025, an estimated $5.22K.
  • Point72 (DIFC) first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 4 quarters.
  • Point72 (DIFC)'s Kyverna Therapeutics position peaked at $1.51M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.